Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

NCT05886049 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

28

Enrollment

NIH

Sponsor class

Conditions

Acute Myeloid Leukemia With KMT2A Rearrangement
Acute Myeloid Leukemia With NPM1 Mutation

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Cytarabine
DRUG: Daunorubicin
PROCEDURE: Multigated Acquisition Scan
DRUG: Revumenib
PROCEDURE: Transthoracic Echocardiography Test

Sponsor

National Cancer Institute (NCI)